AS ONE Corporation (JP:7476)
:7476
Top Page
AS ONE
(7476)
Select Model
Select Model
Rating:76Outperform
Price Target:
¥2,491.00
▲(0.85% Upside)
Action:ReiteratedDate:10/31/25
AS ONE's overall stock score is driven primarily by its strong financial performance, which is supported by robust revenue growth, profitability, and a stable balance sheet. The technical analysis indicates a positive trend, while the valuation is fair, reflecting the company's solid market position. The absence of earnings call data and corporate events does not impact the score.
Positive Factors
Balance sheet strength
Very low leverage and a high equity ratio provide durable financial flexibility. A 12.34% ROE indicates efficient use of shareholder capital. This balance-sheet footing supports investment, M&A or downturn resilience without large external financing needs over the next 2–6 months.
Negative Factors
Falling cash reserves
Although leverage is low, a noted decline in cash reserves creates a tangible liquidity risk if working capital needs rise or receivables/inventory worsen. Reduced cash buffers can constrain near-term operational flexibility and delay strategic investments without external funding.
Read all positive and negative factors
Positive Factors
Negative Factors
Balance sheet strength
Very low leverage and a high equity ratio provide durable financial flexibility. A 12.34% ROE indicates efficient use of shareholder capital. This balance-sheet footing supports investment, M&A or downturn resilience without large external financing needs over the next 2–6 months.
Read all positive factors
AS ONE (7476) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥160.51B
Dividend Yield2.6%
Average Volume (3M)216.80K
Price to Earnings (P/E)18.0
Beta (1Y)0.59
Revenue Growth6.48%
EPS Growth12.88%
CountryJP
Employees711
SectorHealthcare
Sector Strength45
IndustryMedical - Distribution
Share Statistics
EPS (TTM)33.40
Shares Outstanding75,012,540
10 Day Avg. Volume233,440
30 Day Avg. Volume216,803
Financial Highlights & Ratios
PEG Ratio1.86
Price to Book (P/B)2.49
Price to Sales (P/S)1.60
P/FCF Ratio20.48
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)135.23
Revenue Forecast (FY)¥116.65B
AS ONE Business Overview & Revenue Model
Company Description
AS ONE Corporation engages in the sale of research instruments and equipment, nursing and care products, and other scientific instruments in Japan and internationally. It offers scientific instruments comprising temperature/humidity control and me...
How the Company Makes Money
AS ONE primarily makes money through the distribution and sale of products used in laboratories, healthcare, and industrial research and production environments. Its core revenue stream is product sales: the company procures items from manufacture...
AS ONE Financial Statement Overview
Summary
Income Statement
85
Very Positive
Balance Sheet
78
Positive
Cash Flow
80
Positive
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 105.22B | 103.75B | 95.54B | 91.42B | 86.95B | 81.61B |
| Gross Profit | 31.93B | 31.32B | 29.25B | 28.45B | 25.54B | 25.93B |
| EBITDA | 13.78B | 13.39B | 12.26B | 13.04B | 11.07B | 11.59B |
| Net Income | 8.55B | 8.23B | 7.50B | 8.11B | 7.20B | 5.99B |
Balance Sheet | ||||||
| Total Assets | 96.79B | 101.72B | 95.83B | 97.48B | 96.11B | 94.23B |
| Cash, Cash Equivalents and Short-Term Investments | 20.52B | 22.57B | 13.89B | 18.61B | 19.22B | 17.85B |
| Total Debt | 6.58B | 7.21B | 3.65B | 6.27B | 3.19B | 4.82B |
| Total Liabilities | 29.24B | 35.01B | 31.17B | 33.51B | 29.95B | 31.46B |
| Stockholders Equity | 67.55B | 66.71B | 64.66B | 63.97B | 66.15B | 62.76B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | 8.11B | 5.55B | 6.40B | 8.21B | 3.73B |
| Operating Cash Flow | 0.00 | 9.31B | 6.50B | 6.97B | 8.84B | 5.38B |
| Investing Cash Flow | 0.00 | 850.00M | -1.93B | -367.98M | 591.15M | -2.12B |
| Financing Cash Flow | 0.00 | -659.00M | -9.04B | -7.28B | -5.16B | 11.31M |
AS ONE Technical Analysis
Positive
2470.00
Price Trends
2254.00
Negative
2338.24
Negative
2387.53
Negative
Market Momentum
-8.54
Negative
52.23
Neutral
61.78
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:7476, the sentiment is Positive. The current price of 2470 is above the 20-day moving average (MA) of 2234.47, above the 50-day MA of 2254.00, and above the 200-day MA of 2387.53, indicating a neutral trend. The MACD of -8.54 indicates Negative momentum. The RSI at 52.23 is Neutral, neither overbought nor oversold. The STOCH value of 61.78 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:7476.
AS ONE Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
78 Outperform | ¥496.25B | 5.40 | 6.92% | 2.69% | 5.11% | -20.51% | |
76 Outperform | ¥160.51B | 17.99 | 12.55% | 2.60% | 6.48% | 12.88% | |
75 Outperform | ¥216.40B | 15.29 | 9.53% | 2.19% | 8.90% | -3.71% | |
65 Neutral | ¥255.42B | 36.37 | ― | 1.92% | 4.31% | 96.31% | |
62 Neutral | ¥268.62B | 5.59 | 4.38% | 2.03% | 6.04% | 733.13% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | ¥141.30B | 28.05 | 2.42% | 3.73% | 0.04% | ― |
* Healthcare Sector Average
JP:7476
AS ONE
2,260.00
116.26
5.42%
JP:2784
Alfresa Holdings
2,600.50
724.47
38.62%
JP:8086
Nipro
1,647.00
406.42
32.76%
JP:3360
Ship Healthcare Holdings
2,486.50
657.98
35.98%
JP:6523
PHC Holdings Corp.
1,115.00
269.29
31.84%
JP:6849
Nihon Kohden Corporation
1,530.00
-139.38
-8.35%
AS ONE Corporate Events
AS ONE Retires 340,000 Treasury Shares to Streamline Capital Structure
Mar 31, 2026
AS ONE CORPORATION has completed the retirement of 340,000 shares of its common stock, representing 0.45% of the total shares outstanding before the transaction, pursuant to Article 178 of the Companies Act. Effective March 31, 2026, the move redu...
AS ONE Posts February Sales Growth on Strong Scientific and Industrial Demand
Mar 12, 2026
AS ONE Corporation reported a 5.1% year-on-year increase in February 2026 net sales per day, underscoring solid growth in its core scientific and industrial supply businesses. The company highlighted that consumables demand is sensitive to the num...
AS ONE to Cancel Treasury Shares in Capital Efficiency Move
Mar 11, 2026
AS ONE CORPORATION announced it will cancel 340,000 shares of its common stock, representing 0.45% of its issued shares, under Article 178 of the Companies Act of Japan, with the effective date set for March 31, 2026. Following the cancellation, t...
AS ONE Posts 6.8% January Sales Gain on Strong Scientific and Industrial Demand
Feb 12, 2026
AS ONE reported that January 2026 non-consolidated net sales rose 6.8% year on year, with particularly strong performances in the Scientific and Industrial sectors. Scientific sector sales climbed 10.6% and Industrial sector sales grew 4.9%, suppo...
AS ONE Extends Record Profit Streak on Strong E-Commerce and Scientific Instrument Demand
Jan 30, 2026
AS ONE reported a 5.1% year-on-year rise in net sales and a 6.2% increase in gross profit for the third quarter of the fiscal year ending March 2026, with gross margin improving by 0.3 percentage points on better profitability in long-tail and imp...
AS ONE Delivers Higher Nine-Month Profits and Confirms Full-Year Outlook
Jan 30, 2026
AS ONE reported consolidated net sales of ¥79.2 billion for the nine months ended December 31, 2025, up 5.1% year on year, with operating profit rising 12.4% to ¥9.4 billion and profit attributable to owners of parent increasing 12.4% to...
AS ONE Posts 9% December Sales Growth on Strong Scientific and Medical Demand
Jan 30, 2026
AS ONE reported strong non-consolidated net sales for December 2025, with overall sales rising 9.0% year on year, supported by growth in all three of its core sectors. The Scientific Sector led performance with a 12.1% increase driven by the expan...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.